You can Subscribe to our RSS FEED:
which delivers brain tumor news and additions
to the website via RSS.
Click HERE for details on RSS.
Displaying items 1 to 25 of about 5234
KIYATEC Marks Glioblastoma Awareness Day by Initiating Use of 3D Predict™ Glioma Test Outside of Clinical Study
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
Nivolumab Plus Standard- or Reduced-Dosed Bevacizumab for Recurrent Glioblastoma
Musella Foundation awards two brain tumor research grants!
Prolonged survival after laser interstitial thermal therapy in glioblastoma
Kansas advocate for brain cancer patients dies at 22 after giving voice to sick kids
Virtualtrials.org website update
Updated most of the survivor stories!
Safety and Efficacy of Vorasidenib in Recurrent or Progressive Glioma
Adjuvant—Not Concurrent—Temozolomide Upped Overall Survival in 1p/19q Non–Co-Deleted Anaplastic Glioma: Commentary on the CATNON Trial
First Glioblastoma Patient Treated in Focused Ultrasound Clinical Trial at University of Virginia
Musella Foundation Copay Assistance Program is now open!
Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data
Virtual Trials: Causally-validated treatment effects efficiently learned from an observational brain cancer registry
Costly brain cancer drug no longer covered by Medicare
Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay
Save the Date! Promo Discount Code for National Walk To End Brain Tumors: Clark, NJ 7/24/21
Veliparib + RT + TMZ in Patients With Unmethylated MGMT Glioblastoma
Oncolytic Virus Teserpaturev Approved in Japan for Malignant Glioma
Promising New Legislation Could Transform the FDA`s Drug Approval Process, Leading to Better Treatments and Lower Prices
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
Y-mAbs Announces Update on Omburtamab for DIPG
Musella Foundation awards two more brain tumor research grants!
Market Research Opportunity for Patients and Caregivers
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma
Brain Tumor News Blast
Enter your email address to subscribe!
Copyright © 1993 - 2021 Musella Foundation- All Rights Reserved.
Website by LcsProductionDesign.com